KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Cost of Revenue: 2009-2024

Historic Cost of Revenue for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to $42.0 million.

  • Nektar Therapeutics' Cost of Revenue fell 6.50% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.5 million, marking a year-over-year increase of 5.64%. This contributed to the annual value of $42.0 million for FY2024, which is 13.49% up from last year.
  • Latest data reveals that Nektar Therapeutics reported Cost of Revenue of $42.0 million as of FY2024, which was up 13.49% from $37.0 million recorded in FY2023.
  • Over the past 5 years, Nektar Therapeutics' Cost of Revenue peaked at $42.0 million during FY2024, and registered a low of $19.5 million during FY2020.
  • Over the past 3 years, Nektar Therapeutics' median Cost of Revenue value was $37.0 million (recorded in 2023), while the average stood at $33.6 million.
  • As far as peak fluctuations go, Nektar Therapeutics' Cost of Revenue declined by 13.10% in 2022, and later soared by 71.24% in 2023.
  • Nektar Therapeutics' Cost of Revenue (Yearly) stood at $19.5 million in 2020, then increased by 27.83% to $24.9 million in 2021, then decreased by 13.10% to $21.6 million in 2022, then spiked by 71.24% to $37.0 million in 2023, then rose by 13.49% to $42.0 million in 2024.